What is the recommended Norursodeoxycholic acid (NorUDCA) regimen, monitoring schedule, and discontinuation criteria for adults with biopsy‑confirmed metabolic dysfunction‑associated steatohepatitis (MASLD) who have persistent ALT elevation or early‑to‑moderate fibrosis despite optimal lifestyle therapy?

Norursodeoxycholic Acid (NorUDCA) in MASLD: Current Evidence

NorUDCA cannot be recommended for MASLD treatment based on current evidence, as it is not mentioned in the most recent 2024 EASL-EASD-EASO guidelines and lacks phase III trial data demonstrating histological efficacy in metabolic dysfunction-associated steatohepatitis. 1

Why NorUDCA Is Not Recommended

The 2024 EASL-EASD-EASO guidelines explicitly state that only resmetirom has sufficient evidence from large phase III trials to be recommended as MASH-targeted therapy for non-cirrhotic patients with significant fibrosis (stage ≥F2). 1 The guidelines systematically rejected other agents—including vitamin E, pioglitazone, and GLP-1 receptor agonists—specifically because they lack "robust demonstration of histological efficacy on steatohepatitis and liver fibrosis derived from large phase III trials." 1

NorUDCA falls into this same category of insufficient evidence for MASLD.

Available Evidence on NorUDCA

What the Research Shows

The only relevant study for MASLD is a 2019 phase II trial that tested norUDCA in 198 patients with non-alcoholic fatty liver disease. 2 Key findings:

• Primary endpoint: ALT reduction (not histological improvement)
• Results: 1500 mg daily reduced ALT by 27.8% over 12 weeks
• Limitations:
  • Short duration (12 weeks)
  • Surrogate endpoint only (ALT, not fibrosis or steatohepatitis resolution)
  • No histological data
  • Phase II only—no phase III confirmation

NorUDCA's Actual Indication

NorUDCA has been studied primarily for primary sclerosing cholangitis (PSC), a cholestatic bile duct disease, where it showed alkaline phosphatase reduction in phase II trials. 3, 4 This is a fundamentally different disease mechanism than MASLD, which is driven by metabolic dysfunction, not cholestasis.

What IS Recommended for MASLD

Based on the 2024 guidelines, the treatment hierarchy is: 1

First-Line: Lifestyle Modification

• Weight loss: 7-10% body weight reduction
• Diet: Mediterranean pattern, limit ultra-processed foods
• Exercise: ≥150 min/week moderate or 75 min/week vigorous activity

Pharmacotherapy (Non-Cirrhotic MASH with F2-F3 Fibrosis)

• Resmetirom: Only agent with strong recommendation if locally approved
• GLP-1 receptor agonists: Use for diabetes/obesity indications (improves cardiometabolic outcomes, may benefit liver with substantial weight loss)
• Pioglitazone: Safe to use but cannot be recommended as MASH-targeted therapy
• SGLT2 inhibitors/Metformin: Use for diabetes/heart failure/CKD indications, not as MASH therapy

What NOT to Use

• Vitamin E: Rejected due to lack of phase III efficacy and long-term safety concerns 1
• Nutraceuticals: Insufficient evidence 1
• Non-incretin weight-loss agents: Not recommended 1

Critical Pitfalls to Avoid

1. Do not use ALT reduction as a treatment target: The 2024 guidelines emphasize histological endpoints (steatohepatitis resolution, fibrosis regression) and clinical outcomes (morbidity, mortality), not biochemical markers alone. 1

2. Do not extrapolate from cholestatic disease: NorUDCA's mechanism (cholehepatic shunting, anti-cholestatic effects) addresses bile acid pathology in PSC, not the metabolic inflammation and lipotoxicity driving MASLD. 4

3. Do not use agents without phase III data: The guidelines consistently rejected therapies lacking large, well-conducted phase III trials demonstrating histological benefit—this standard applies equally to norUDCA. 1

If You Must Consider Off-Label Therapy

Given the explicit guideline framework, if a patient has failed lifestyle modification and resmetirom is unavailable or contraindicated:

• Prioritize GLP-1 receptor agonists (semaglutide, tirzepatide) for patients with diabetes or obesity—these have cardiometabolic benefits and potential liver benefit with substantial weight loss 1, 5
• Consider pioglitazone in non-cirrhotic patients despite weak recommendation, as it has more MASLD-specific data than norUDCA 1
• Refer for clinical trials rather than using agents without established efficacy

Monitoring If Resmetirom Is Used

While not norUDCA-specific, the 2024-2026 consensus provides monitoring guidance for approved MASH therapies: 5

• Baseline: Confirm F2-F3 fibrosis by biopsy or non-invasive tests (LSM 10-20 kPa or ELF 9.2-11.3)
• Response assessment at 1 year: ≥30% LSM reduction or ≥0.5-point ELF reduction
• Discontinuation criteria: Lack of response at 1 year, progression to cirrhosis, or intolerable adverse effects

The evidence is clear: norUDCA lacks the phase III histological efficacy data required by current guidelines and should not be used for MASLD outside of clinical trials. Focus instead on proven lifestyle interventions and, when indicated, resmetirom or metabolic agents used for their primary indications.